Related Experiment Video
Updated: Mar 26, 2026
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities
Jorge Franco1, Uthra Balaji1, Elizaveta Freinkman2
1McDermott Center University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390, USA.
Abstract:
Due to loss of p16ink4a in pancreatic ductal adenocarcinoma (PDA), pharmacological suppression of CDK4/6 could represent a potent target for treatment. In PDA models, CDK4/6 inhibition had a variable effect on cell cycle but yielded accumulation of ATP and mitochondria. Pharmacological CDK4/6 inhibitors induce cyclin D1 protein levels; however, RB activation was required and sufficient for mitochondrial accumulation. CDK4/6 inhibition stimulated glycolytic and oxidative metabolism and was associated with an increase in mTORC1 activity. MTOR and MEK inhibitors potently cooperate with CDK4/6 inhibition in eliciting cell-cycle exit. However, MTOR inhibition fully suppressed metabolism and yielded apoptosis and suppression of tumor growth in xenograft models. The metabolic state mediated by CDK4/6 inhibition increases mitochondrial number and reactive oxygen species (ROS). Concordantly, the suppression of ROS scavenging or BCL2 antagonists cooperated with CDK4/6 inhibition. Together, these data define the impact of therapeutics on PDA metabolism and provide strategies for converting cytostatic response to tumor cell killing.
Insights
Targeting CDK4/6 in pancreatic cancer may boost cell metabolism, increasing ATP and mitochondria. Combining CDK4/6 inhibitors with other drugs can enhance anti-cancer effects and promote tumor cell death.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metabolism
Background:
- Pancreatic ductal adenocarcinoma (PDA) often involves p16ink4a loss, making CDK4/6 a potential therapeutic target.
- CDK4/6 inhibitors have shown variable effects on cell cycle progression in PDA models.
Purpose of the Study:
- To investigate the metabolic consequences of CDK4/6 inhibition in PDA.
- To identify combination strategies to convert cytostatic responses into tumor cell killing.
Main Methods:
- Utilized PDA models to assess the effects of CDK4/6 inhibition on cell cycle, metabolism, and mitochondrial function.
- Investigated the role of RB activation in mediating metabolic changes.
- Evaluated the efficacy of combining CDK4/6 inhibitors with mTOR, MEK, ROS scavenging, or BCL2 antagonists.
Main Results:
- CDK4/6 inhibition led to ATP accumulation, increased mitochondrial content, and stimulated both glycolytic and oxidative metabolism.
- RB activation was necessary and sufficient for CDK4/6 inhibition-induced mitochondrial accumulation.
- Combined inhibition of mTOR with CDK4/6 resulted in apoptosis and suppressed tumor growth in xenograft models.
- Increased reactive oxygen species (ROS) production was observed under CDK4/6 inhibition, and its suppression enhanced therapeutic effects.
Conclusions:
- CDK4/6 inhibition significantly alters PDA cell metabolism, increasing mitochondrial biogenesis and ROS production.
- Combination therapies targeting mTOR, ROS scavenging, or BCL2 antagonists alongside CDK4/6 inhibition can overcome cytostatic effects and promote tumor cell death.
